Loading…
Loading…
Repligen Corporation (RGEN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?
Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.
American Capital Management Inc. acquired a new position in shares of Repligen Corporation (NASDAQ: RGEN) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 361,055 shares of the biotechnology company's stock, valued at approximately $49,262,000. Repligen comprises
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, RGEN, IOVA, ARQT and PGEN in this volatile sector.
WALTHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the Wells Fargo 21st Annual Healthcare Conference in Boston, MA. Olivier Loeillot, President and Chief Executive Officer and Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion on September 9th at 1:30 p.m. ET.
Bank of Nova Scotia acquired a new stake in Repligen Corporation (NASDAQ: RGEN) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 25,992 shares of the biotechnology company's stock, valued at approximately $3,547,000. Several other institutional investors have also modified their holdings
On August 19, 2026, Merck (NYSE:MRK | MRK Price Prediction) and Moderna (NASDAQ:MRNA) announced positive topline Phase 3 results from INTerpath-001 for intismeran autogene, an individualized neoantigen therapy paired with Keytruda in resected melanoma.